RECORDATI – APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE ANNOUNCEMENT AND DRAFT RESOLUTIONS FOR THE GENERAL MEETING OF APRIL 29, 2022.

PRESS RELEASE

REGISTRATION APPOINTMENT OF THE BOARD OF DIRECTORS: PUBLICATION OF THE LIST AND PROPOSED RESOLUTIONS FOR SHAREHOLDERS MEETING OF APRIL 29, 2022.

Milan, April 8, 2022 With reference to the Ordinary General Meeting of Recordati SpA (“Registration“or the”Company“) called on April 29, 2022, in a single call, (the “Meeting of shareholders“)

please note that, under the terms of the law, a single list composed of 12 candidates (there “Slate“), for the appointment of the Board of Directors was submitted by the shareholder Rossini S. à rl

(“Rossini“), holder of no. 108,368,721 ordinary shares of Recordati, i.e. 51.820% of the capital concerned shares the capital.

The List also contains the proposed resolutions of the shareholder Rossini on points 2.a) and 2.b) on the agenda of the General Meeting relating to the determination in 12 of the number of

members of the Board of Directors and the term of office for the 2022-2024 financial years.

Rossini, after learning of the sudden unavailability, for personal reasons, of the candidate registered for the last post of the Slate, submitted a motion for a resolution in accordance with article 126-bis, paragraph 1, penultimate sentence, of Legislative Decree 58/1998 (“TUFF“) containing (i) the name of a new nominee for the position of director of Recordati as the twelfth member of the board of directors, which will be voted on by the General Assembly following the vote of the Slate; (ii) the proposed resolution relating to the compensation of the members of the Board of Directors.

The candidates are:

  • 9. Michaela Castelli

  • ;

  • 10. Piergiorgio Peluso

  • ;

11. Luigi Felice La Corte;

12. Elisa Corghi

.

Candidate having declared that he meets the conditions of independence provided for by law and the Code of Corporate Governance. RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SpA Registration desk

Via Matteo Civitali, 1

Share the capital

€26,140,644.50

fully released

20148 Milan, Italy

Milan, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Telephone (39) 02 487871

Tax code/VAT number 00748210150

Fax (39) 02 40073747

Milan REA No. 401832 www.recordati.comCompany subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.lThe first eleven candidates are taken from the list, the twelfth candidate is taken from the motion for a resolution above. The List, containing the proposed resolutions relating to the number of members of the Board of Directors and the term of office of the board of directors itself, the draft resolution submitted pursuant to article 126- bisparagraph 1, penultimate sentence, of the TUF relating to the appointment of the new candidate and the remuneration of the Boardas well as the documentation required by law and regulations– are accessible to the public at Recordati’s registered office, on the Company’s website (

www.recordati.itunder the heading “Investor/Shareholder Meetings

“), as well as on thestorage mechanism 1INFO (www.1info.it ).

On the Company’s website (

www.recordati.itunder the same section) are also available the proxy forms for the designated representative that take into account the proposal of the resolution finallypresented by the shareholder Rossini.Registration, created in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total workforce of more than 4,300 people, dedicated to research, development, manufacturing and marketing of pharmaceutical products. Based in Milan, Italy, Recordati is present in Europe, Russia and other CIS countries, Ukraine, Turkey, North Africa, United States of America, Canada, Mexico, some South American countries, Japan and Australia. An effective field force of medical visitors promotes a wide range of innovative, proprietary and licensed pharmaceutical products in several therapeutic areas, including a specialist business dedicated to rare disease treatments. Recordati is a partner of choice for licensing new products for its territories. Recordati engages in the research and development of new specialties with an emphasis on treatments for rare diseases. Consolidated turnover 2021 was €1,580.1 million, operati

ng income was €4

90.2 million and the net result was €3

86.0 million.

For more information:Recordati website: www.recordati.it Investor Relations Investor Relations Media Relations Federica De Medici Lucia Abbatantuoni Brunswick : Barbara Scalchi / Andrea Mormandi (39) 02 48787146 (39) 02 48787213 (39) 02 9288 6200 [email protected]

E-mail:

[email protected]:[email protected]

Jacob L. Thornton